ReviewWorld journal of hepatology2017
Drug-induced liver injury: Do we know everything?
Review in World journal of hepatology, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 33 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
33 citing papers in PubMed.
- Article
- Drug-Induced Liver Injury with Novel Fat Burner AlbutarexV2 in an Active Duty Sailor.Military medicine · 2026Article
- SSRIs-induced liver injury adverse events: a data-based retrospective study and investigation of potential toxicological mechanisms.Frontiers in pharmacology · 2026Article
- Selenium Ameliorates Acetaminophen-Induced Oxidative Stress via MAPK and Nrf2 Pathways in Mice.Biological trace element research · 2024Article
- Antioxidative and Anti-Inflammatory Protective Effects of Fucoxanthin against Paracetamol-Induced Hepatotoxicity in Rats.Marine drugs · 2023Article
- Advances in Idiosyncratic Drug-Induced Liver Injury Issues: New Clinical and Mechanistic Analysis Due to Roussel Uclaf Causality Assessment Method Use.International journal of molecular sciences · 2023Review
- Computational models for predicting liver toxicity in the deep learning era.Frontiers in toxicology · 2023Review
- Potential deleterious effects of paracetamol dose regime used in Nigeria versus that of the United States of America.Toxicology reports · 2022Review
- Imaging of the chemotherapy-induced hepatic damage: Yellow liver, blue liver, and pseudocirrhosis.World journal of gastroenterology · 2021Article
- Hepatotoxicity reports in the FDA adverse event reporting system database: A comparison of drugs that cause injuryActa pharmaceutica Sinica. B · 2021Article
- The application of cytokeratin-18 as a biomarker for drug-induced liver injury.Archives of toxicology · 2021Review
- Metabolic Forest: Predicting the Diverse Structures of Drug Metabolites.Journal of chemical information and modeling · 2020Article
- Dietary Iron Overload Differentially Modulates Chemically-Induced Liver Injury in Rats.Nutrients · 2020Article
- Secondary Sclerosing Cholangitis in Critically Ill Patients: An Underdiagnosed Entity.GE Portuguese journal of gastroenterology · 2020Review
- Drug-Induced Liver Injury in Critically Ill Children Taking Antiepileptic Drugs: A Retrospective Study.Current therapeutic research, clinical and experimental · 2020Article
- A possible increase in liver enzymes due to amlodipine: A case report.SAGE open medical case reports · 2020Article
- Induced pluripotent stem cells for therapy personalization in pediatric patients: Focus on drug-induced adverse events.World journal of stem cells · 2019Review
- A Rare Presentation of Drug-induced Liver Injury with Fluticasone and Vilanterol Inhaler Use.Cureus · 2019Article
- Mifepristone: An Uncommon Cause of Drug-Induced Liver Injury.Gastroenterology research · 2019Article
- Carvedilol-Induced Liver Injury, a Rare Cause of Mixed Hepatitis: A Clinical Case.GE Portuguese journal of gastroenterology · 2019Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Interest in drug-induced liver injury (DILI) has dramatically increased over the past decade, and it has become a hot topic for clinicians, academics, pharmaceutical companies and regulatory bodies. By investigating the current state of the art, the latest scientific findings, controversies, and guidelines, this review will attempt to answer the question: Do we know everything? Since the first descriptions of hepatotoxicity over 70 years ago, more than 1000 drugs have been identified to date, however, much of our knowledge of diagnostic and pathophysiologic principles remains unchanged. Clinically ranging from asymptomatic transaminitis and acute or chronic hepatitis, to acute liver failure, DILI remains a leading causes of emergent liver transplant. The consumption of unregulated herbal and dietary supplements has introduced new challenges in epidemiological assessment and clinician management. As such, numerous registries have been created, including the United States Drug-Induced Liver Injury Network, to further our understanding of all aspects of DILI. The launch of LiverTox and other online hepatotoxicity resources has increased our awareness of DILI. In 2013, the first guidelines for the diagnosis and management of DILI, were offered by the Practice Parameters Committee of the American College of Gastroenterology, and along with the identification of risk factors and predictors of injury, novel mechanisms of injury, refined causality assessment tools, and targeted treatment options have come to define the current state of the art, however, gaps in our knowledge still undoubtedly remain.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.